Vita Coco (NASDAQ: COCO) CEO sells 50,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vita Coco Company, Inc. Chief Executive Officer Martin Roper reported a series of option exercises and share sales in company stock. On April 24 and April 27, he exercised stock options to acquire a total of 50,000 shares of common stock at an exercise price of $10.178 per share and sold 50,000 shares of common stock in open-market transactions at $50.00 per share. Following these transactions, he directly holds 298,484 shares of common stock, with additional indirect holdings reported by his spouse and several Exempt Family Trusts. The filing notes that the sales under these transactions were effected pursuant to a Rule 10b5-1 trading plan, indicating they were pre-scheduled under a pre-arranged trading program.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 50,000 shares ($2,500,000)
Net Sell
16 txns
Insider
Roper Martin
Role
Chief Executive Officer
Sold
50,000 shs ($2.50M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Exercise | Common Stock | 25,000 | $10.178 | $254K |
| Sale | Common Stock | 25,000 | $50.00 | $1.25M |
| Exercise | Non-Qualified Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Exercise | Common Stock | 25,000 | $10.178 | $254K |
| Sale | Common Stock | 25,000 | $50.00 | $1.25M |
| holding | Non-Qualified Stock Option (Right to Buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (Right to Buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (Right to Buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (Right to Buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (Right to Buy) | -- | -- | -- |
| holding | Non-Qualified Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 375,214 shares (Direct, null);
Common Stock — 323,484 shares (Direct, null);
Common Stock — 215,631 shares (Indirect, by Chris Roper FT)
Footnotes (1)
- The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan. These shares are held by the Christopher G. Roper Exempt Family Trust. These shares are held by the Peter S. Roper Exempt Family Trust. These shares are held by the Thomas L. Roper Exempt Family Trust. The stock option is fully vested and currently exercisable. The stock option vests in four equal annual installments beginning on November 27, 2022. The stock option vests in four equal annual installments beginning on March 10, 2024. The stock option vests in four equal annual installments beginning on March 4, 2025. The stock option vests in four equal annual installments beginning on March 3, 2026.
Key Figures
Shares sold: 50,000 shares
Sale price: $50.00 per share
Options exercised: 50,000 shares
+5 more
8 metrics
Shares sold
50,000 shares
Open-market sales of common stock at $50.00 per share
Sale price
$50.00 per share
Price for common stock sales on April 24 and April 27
Options exercised
50,000 shares
Stock options exercised at $10.178 per share
Exercise price
$10.178 per share
Exercise price for non-qualified stock options converted to common stock
Direct holdings after trades
298,484 shares
Common stock directly held by CEO following transactions
Option position at $15.00
298,507 underlying shares
Non-qualified stock option, $15.0000 exercise price, expiring 2031-10-21
Option position at $16.91
185,133 underlying shares
Non-qualified stock option, $16.9100 exercise price, expiring 2033-03-10
Option position at $32.78
70,715 underlying shares
Non-qualified stock option, $32.7800 exercise price, expiring 2035-03-03
Key Terms
Rule 10b5-1 trading plan, Non-Qualified Stock Option (Right to Buy), Exempt Family Trust, derivative exercise/conversion, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option (Right to Buy) financial
"security_title": "Non-Qualified Stock Option (Right to Buy)""
Exempt Family Trust financial
"These shares are held by the Christopher G. Roper Exempt Family Trust."
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What did Vita Coco (COCO) CEO Martin Roper report in this Form 4 filing?
Martin Roper reported exercising stock options and selling company shares. He exercised 50,000 options at $10.178 per share and sold 50,000 common shares at $50.00 per share in open-market transactions disclosed in the filing.
What stock options did the Vita Coco (COCO) CEO exercise in this Form 4?
He exercised options to acquire 50,000 Vita Coco common shares at an exercise price of $10.178 per share. These option exercises converted derivative awards into common stock, which was then partially or fully sold in open-market transactions.
What remaining stock options does the Vita Coco (COCO) CEO have outstanding?
The filing lists several remaining non-qualified stock options. Examples include options over 298,507 underlying shares at an exercise price of $15.0000 and options over 185,133 underlying shares at $16.9100, with expirations extending into 2033 and 2031.